Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Active, not recruiting · NCT02537418 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | Solid Malignancies | Active, not recruiting | Phase 1 | 2026-03-27 | NCT02537418 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Canadian Cancer Trials Group | 73 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCCA - Vancouver Cancer Centre | Vancouver | Canada | 11 |
| Cancer Centre of Southeastern Ontario at Kingston | Kingston | Canada | 3 |
| CHUM - Hopital Notre-Dame | Montreal | Canada | 10 |
| Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Canada | 60 |
| Ottawa Hospital Research Institute | Ottawa | Canada | 46 |
| Tom Baker Cancer Centre | Calgary | Canada | 29 |
| University Health Network | Toronto | Canada | 52 |